{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:49:35Z","timestamp":1790657375358,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ctrv.2020.102060","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T03:13:34Z","timestamp":1592882014000},"page":"102060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications"],"prefix":"10.1016","volume":"88","author":[{"given":"Daniela","family":"Massi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Mihic-Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102060_b0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00428-018-2506-y","article-title":"Rational combination of cancer immunotherapy in melanoma","volume":"474","author":"Mandal\u00e0","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2020.102060_b0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00428-013-1526-x","article-title":"Tissue prognostic biomarkers in primary cutaneous melanoma","volume":"464","author":"Mandal\u00e0","year":"2014","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.ctrv.2020.102060_b0015","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual: melanoma staging: AJCC 8 th Edition","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2020.102060_b0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/PAS.0000000000000527","article-title":"Metastatic malignant melanoma with complete loss of differentiation markers (undifferentiated\/dedifferentiated melanoma): analysis of 14 patients emphasizing phenotypic plasticity and the value of molecular testing as surrogate diagnostic marker","volume":"40","author":"Agaimy","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.ctrv.2020.102060_b0025","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.molmed.2006.07.008","article-title":"MITF: master regulator of melanocyte development and melanoma oncogene","volume":"12","author":"Levy","year":"2006","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ctrv.2020.102060_b0030","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1242\/dev.123729","article-title":"The melanocyte lineage in development and disease","volume":"142","author":"Mort","year":"2015","journal-title":"Development"},{"key":"10.1016\/j.ctrv.2020.102060_b0035","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41568-019-0154-4","article-title":"Phenotype plasticity as enabler of melanoma progression and therapy resistance","volume":"19","author":"Arozarena","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2020.102060_b0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2020.102060_b0045","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/0008-5472.CAN-07-2491","article-title":"In vivo switching of human melanoma cells between proliferative and invasive states","volume":"68","author":"Hoek","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102060_b0050","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/pcmr.12370","article-title":"Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy","volume":"28","author":"Wellbrock","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102060_b0055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/labinvest.2017.9","article-title":"The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology","volume":"97","author":"Kawakami","year":"2017","journal-title":"Lab Invest"},{"key":"10.1016\/j.ctrv.2020.102060_b0060","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/CMR.0000000000000195","article-title":"Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival","volume":"25","author":"Naffouje","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102060_b0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/exd.12724","article-title":"Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation","volume":"24","author":"Vachtenheim","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ctrv.2020.102060_b0070","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"M\u00fcller","year":"2014","journal-title":"Nature Commun"},{"key":"10.1016\/j.ctrv.2020.102060_b0075","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4103\/0377-4929.107806","article-title":"A case of collision tumor or transdifferentiation between malignant melanoma and leiomyosarcoma","volume":"55","author":"Ul-Mulk","year":"2012","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.ctrv.2020.102060_b0080","first-page":"1658","article-title":"Micropthalmia Transcription Factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers","volume":"6","author":"Guo","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.ctrv.2020.102060_b0085","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/his.12305","article-title":"BRAF mutation in \u2018sarcomas\u2019: a possible method to detect de-differentiated melanomas","volume":"64","author":"Cipriani","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2020.102060_b0090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00428-014-1542-5","article-title":"Metastatic melanoma mimicking solitary fibrous tumor: report of two cases","volume":"464","author":"Bekers","year":"2014","journal-title":"Virch Archiv"},{"key":"10.1016\/j.ctrv.2020.102060_b0095","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/jdv.13155","article-title":"Effective treatment with Dabrafenib and Trametinib for a BRAF-mutated metastatic dedifferentiated malignant spindle cell neoplasm","volume":"30","author":"Escandell","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ctrv.2020.102060_b0100","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/DAD.0000000000000619","article-title":"Altered morphology and immunohistochemical characteristics in metastatic malignant melanoma after therapy with vemurafenib","volume":"38","author":"Powell","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.ctrv.2020.102060_b0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41379-018-0161-0","article-title":"Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma","volume":"32","author":"Alrabadi","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2020.102060_b0110","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/cup.13539","article-title":"Malignant melanoma with metaplastic cartilaginous transdifferentiation: A case report","volume":"46","author":"Berro","year":"2019","journal-title":"J Cut Pathol"},{"key":"10.1016\/j.ctrv.2020.102060_b0115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/PAS.0b013e31822280d8","article-title":"Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma","volume":"5","author":"Jalas","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2020.102060_b0120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13256-017-1238-y","article-title":"The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report","volume":"11","author":"R\u00f8e","year":"2017","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.ctrv.2020.102060_b0125","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00428-018-2376-3","article-title":"New observations in tumor cell plasticity: mutational profiling in a case of metastatic melanoma with biphasic sarcomatoid transdifferentiation","volume":"473","author":"Rupp","year":"2018","journal-title":"Virch Archiv"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102060_b0130","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/DAD.0000000000001322","article-title":"Dedifferentiated melanoma with expression of cytokeratin and GATA3 in a patient with history of breast carcinoma","volume":"41","author":"Alkhasawneh","year":"2019","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.ctrv.2020.102060_b0135","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/DAD.0b013e31819afdaa","article-title":"Kazakov DV. Metastatic desmoplastic malignant melanoma associated with low-grade myofibroblastic sarcoma","volume":"31","author":"Kacerovska","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.ctrv.2020.102060_b0140","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMc0707079","article-title":"Malignant melanoma with metastatic rhabdomyosarcomatoid transdifferentiation","volume":"358","author":"Gattenl\u00f6hner","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102060_b0145","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1066896913510031","article-title":"Rhabdomyoblastic differentiation in metastatic melanoma: making sense of a rare but complex form of mimicry","volume":"22","author":"Reilly","year":"2014","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.ctrv.2020.102060_b0150","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/cup.13122","article-title":"Metastatic melanoma with dedifferentiation and extensive rhabdomyosarcomatous heterologous component","volume":"45","author":"Campbell","year":"2018","journal-title":"J Cut Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2020.102060_b0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/CMR.0000000000000636","article-title":"Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy","volume":"30","author":"Prior","year":"2020","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.ctrv.2020.102060_b0160","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/1066896919839143","article-title":"Undifferentiated sarcoma as intermediate step in rhabdomyosarcomatous transformation of a metastatic malignant melanoma resistant to anti-BRAF therapy: A phenomenon associated with significant diagnostic and therapeutic pitfalls","volume":"27","author":"Tran","year":"2019","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.ctrv.2020.102060_b0165","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0749.2006.00322.x","article-title":"Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature","volume":"19","author":"Hoek","year":"2006","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.ctrv.2020.102060_b0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/pcmr.12710","article-title":"BRN2, a POUerful driver of melanoma phenotype switching and metastasis","volume":"32","author":"Fane","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102060_b0175","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/sj.onc.1208924","article-title":"The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer","volume":"24","author":"Mishra","year":"2005","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102060_b0180","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI94295","article-title":"SMAD signaling promotes melanoma metastasis independently of phenotype switching","volume":"129","author":"Tuncer","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2020.102060_b0185","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2016.02.023","article-title":"Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma","volume":"59","author":"Roesch","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102060_b0190","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/onc.2017.341","article-title":"A slow-cycling subpopulation of melanoma cells with highly invasive properties","volume":"37","author":"Perego","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2020.102060_b0195","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/jnci\/djj103","article-title":"Gene expression profiling of primary cutaneous melanoma and clinical outcome","volume":"98","author":"Winnepenninckx","year":"2006","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.ctrv.2020.102060_b0200","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2020.102060_b0205","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1158\/1078-0432.CCR-12-0343","article-title":"Molecular profiling reveals low- and high-grade forms of primary melanoma","volume":"18","author":"Harbst","year":"2012","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2020.102060_b0210","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-09-2509","article-title":"Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome","volume":"16","author":"J\u00f6nsson","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102060_b0215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10555-017-9658-0","article-title":"Metastatic melanoma moves on: translational science in the era of personalized medicine","volume":"36","author":"Levesque","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2020.102060_b0220","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2020.102060_b0225","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102060_b0230","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102060_b0235","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102060_b0240","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102060_b0245","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1158\/1078-0432.CCR-16-0954","article-title":"Molecular pathways: maintaining MAPK inhibitor sensitivity by targeting nonmutational tolerance","volume":"22","author":"Smith","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102060_b0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/164_2017_17","article-title":"Mechanisms of drug resistance in melanoma","volume":"249","author":"Winder","year":"2018","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.ctrv.2020.102060_b0255","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2020.102060_b0260","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s40425-019-0797-4","article-title":"The density and spatial tissue distribution of CD8\u00b1 and CD163\u00b1 immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors","volume":"7","author":"Massi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2020.102060_b0265","first-page":"665","article-title":"Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination","volume":"62","author":"Hendrix","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102060_b0270","doi-asserted-by":"crossref","first-page":"e33571","DOI":"10.1371\/journal.pone.0033571","article-title":"Tumor cell plasticity and angiogenesis in human melanomas","volume":"7","author":"Mihic-Probst","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2020.102060_b0275","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nature05660","article-title":"Melanocyte biology and skin pigmentation","volume":"445","author":"Lin","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102060_b0280","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1083\/jcb.200505059","article-title":"Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation","volume":"170","author":"Wellbrock","year":"2005","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ctrv.2020.102060_b0285","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature12688","article-title":"A melanocyte lineage program confers resistance to MAP kinase pathway inhibition","volume":"504","author":"Johannessen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102060_b0290","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/pcmr.12741","article-title":"A PAX3\/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh\/AXLlow melanoma","volume":"32","author":"Smith","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102060_b0295","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2020.102060_b0300","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2020.102060_b0305","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2020.102060_b0310","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1158\/0008-5472.CAN-14-1392","article-title":"Inhibition of mTORC1\/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1\u03b1 and oxidative phosphorylation in melanoma","volume":"74","author":"Gopal","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102060_b0315","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2159-8290.CD-13-1007","article-title":"The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF\u03b1","volume":"4","author":"Smith","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2020.102060_b0320","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1172\/JCI65780","article-title":"Melanoma adapts to RAF\/MEK inhibitors through FOXD3-mediated upregulation of ERBB3","volume":"123","author":"Abel","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2020.102060_b0325","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102060_b0330","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102060_b0335","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","article-title":"A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors","volume":"4","author":"Konieczkowski","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2020.102060_b0340","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2020.102060_b0345","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1038\/s41467-018-06951-2","article-title":"Sustained activation of the Aryl hydrocarbon receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma","volume":"9","author":"Corre","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2020.102060_b0350","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward minimal residual disease directed therapy in melanoma","volume":"174","author":"Rambow","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2020.102060_b0355","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102060_b0360","first-page":"680","article-title":"Adjuvant therapy in resected melanoma","volume":"378","author":"Weber","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102060_b0365","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102060_b0370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature09161","article-title":"Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271","volume":"466","author":"Boiko","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102060_b0375","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature11538","article-title":"Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102060_b0380","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/2159-8290.CD-17-1178","article-title":"Immunotherapy Resistance by Inflammation-Induced Dedifferentiation","volume":"8","author":"Mehta","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2020.102060_b0385","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri3064","article-title":"The parallel lives of angiogenesis and immunosuppression: cancer and other tales","volume":"11","author":"Motz","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2020.102060_b0390","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nrm2455","article-title":"Cancer as an overhealing wound: an old hypothesis revisited","volume":"9","author":"Sch\u00e4fer","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2020.102060_b0395","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fonc.2014.00070","article-title":"Control of the immune response by pro-angiogenic factors","volume":"4","author":"Voron","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2020.102060_b0400","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/385810a0","article-title":"Viable offspring derived from fetal and adult mammalian cells","volume":"385","author":"Wilmut","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102060_b0405","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.freeradbiomed.2012.02.043","article-title":"Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain","volume":"52","author":"Yoo","year":"2012","journal-title":"Free Radic Biol Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:24:27Z","timestamp":1759656267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220300980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":81,"alternative-id":["S0305737220300980"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102060","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102060"}}